A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Effect of Mild, Moderate and Severe Renal Impairment on the Pharmacokinetics of YM178.
Phase of Trial: Phase I
Latest Information Update: 04 Sep 2013
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder; Urination disorders
- Focus Pharmacokinetics
- Sponsors Astellas Pharma US
- 07 Oct 2009 Actual patient number (33) added as reported by ClinicalTrials.gov.
- 07 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jul 2009 Planned end date changed from 1 Jul 2009 to 1 Sep 2009 as reported by ClinicalTrials.gov.